EUVIMEDSkopri EUVIMED
Crossref

Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders

Mutong Zhao iD, Yi Zhuang, Yuan Liang, Lin Ma, Chunping Shen

Clinical & Experimental Allergy · 2024

DOI: 10.1111/cea.14518 ↗

At a glance

Journal article in Clinical & Experimental Allergy, 2024. Written by Mutong Zhao and 4 co-authors. Institution: Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic. Cited 6 times so far (Crossref); 9 references. Funded by: Capital's Fund for Health Improvement and Research, Chinese Association of Rehabilitation Medicine's Fund for Technological Improvement, Beijing Natural Science Foundation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Subjects

MeSH terms (MEDLINE)

Antibodies, Monoclonal, HumanizedDermatitis, AtopicAdolescentChildChild, PreschoolFemaleHumansMaleDrug ResistanceHeterocyclic Compounds, 3-RingTreatment Outcome

Author keywords

atopic dermatitisclinical immunologydermatologyepidemiologypediatrics

Substances

Antibodies, Monoclonal, HumanizeddupilumabHeterocyclic Compounds, 3-Ringupadacitinib

Authors and institutions

  • Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

ORCID profiles: Mutong Zhao

Funding

  • Capital's Fund for Health Improvement and Research
  • Chinese Association of Rehabilitation Medicine's Fund for Technological Improvement
  • Beijing Natural Science Foundation
  • Natural Science Foundation of Beijing Municipality

Cite

APA

Zhao, M., Zhuang, Y., Liang, Y., Ma, L., & Shen, C. (2024). Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14518

Vancouver

Zhao M, Zhuang Y, Liang Y, Ma L, Shen C. Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders. Clinical & Experimental Allergy. 2024. doi:10.1111/cea.14518

BibTeX
@article{Zhao2024,
  author = {Zhao, Mutong and Zhuang, Yi and Liang, Yuan and Ma, Lin and Shen, Chunping},
  title = {Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders},
  journal = {Clinical & Experimental Allergy},
  year = {2024},
  doi = {10.1111/cea.14518}
}
Start for free →